Antares Pharma, Inc. (ATRS)
| Market Cap | 955.06M |
| Revenue (ttm) | 183.46M |
| Net Income (ttm) | 40.18M |
| Shares Out | 170.85M |
| EPS (ttm) | 0.23 |
| PE Ratio | 24.09 |
| Forward PE | 50.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,763,417 |
| Open | 5.59 |
| Previous Close | 5.58 |
| Day's Range | 5.58 - 5.59 |
| 52-Week Range | 3.11 - 5.59 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 6.07 (+8.6%) |
| Earnings Date | May 19, 2022 |
About ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheuma...
Financial Performance
In 2021, Antares Pharma's revenue was $183.98 million, an increase of 22.98% compared to the previous year's $149.60 million. Earnings were $46.29 million, a decrease of -17.64%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ATRS stock is "Buy." The 12-month stock price forecast is 6.07, which is an increase of 8.59% from the latest price.
News
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, a...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, PSB, ATRS, VWTR
NEW YORK , May 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of ...
HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA
SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purc...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Antares Pharma, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Antares Pharma, Inc. ("Antares") (NASDAQ: ATRS) regarding possible breaches of fiduciary duties and other v...
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?
Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNK
NEW YORK , April 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.
NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "...
Antares Pharma Inc shares up 45% on Wednesday: how come?
Antares Pharma Inc shares (NASDAQ: ATRS) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The ...
Why Antares Pharma Stock Is Soaring Today
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Ant...
Why Is Antares Pharma (ATRS) Stock Up Today?
Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). The post Why Is Antares Pharma (ATRS) Stock Up Today?
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informa...
Why Antares Pharma Stock Is Bolting Higher Today
The drug delivery specialist has reportedly agreed to a merger with Halozyme.
ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. (NASDAQ: ATRS) to Halozyme Therapeutics, Inc. for $5.60 per share in c...
Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium
Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeuti...
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business wit...
Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral trea...
Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates
Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executiv...
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2...
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute ...
Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”)...
Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior ...
Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-190...
MedMira strengthen its Board with New Appointment
HALIFAX, Nova Scotia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective immediately.